Physician profile
Robert Levine
NPI 1538190731
$4,227.44
in general payments reported to CMS, 2019-2025
48 companies · $567 in 2025
The $567 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $903 · 2020: $130 · 2022: $806 · 2023: $760 · 2024: $1,061 · 2025: $567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,195 · Long Term Medical Supply Or Device Loan: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,195.45 |
| Long Term Medical Supply Or Device Loan | $193.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $835.17 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Abbvie INC. | $525.21 | 2019-2025 | |
| Pfizer INC. | $272.19 | 2019-2025 | |
| Celgene Corporation | $244.03 | 2022-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $213.51 | 2019-2023 | Trulance |
| Pentax of America, INC. | $193.55 | 2024 | Video Colonoscope |
| Medtronic, INC. | $160.49 | 2022-2024 | Minimed 780g |
| E.R. Squibb & Sons, L.L.C. | $124.98 | 2022 | |
| Ferring Pharmaceuticals INC. | $124.91 | 2019-2025 | Rebyota |
| Lilly USA, LLC | $124.88 | 2019-2025 | Omvoh, Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $124.25 | 2019-2025 | Entyvio |
| Genzyme Corporation | $90.51 | 2023-2024 | |
| Sun Pharmaceutical Industries INC. | $90.12 | 2019 | |
| Amgen INC. | $74.99 | 2019-2023 | Evenity, Prolia |
| Qol Medical, LLC | $73.48 | 2025 | Sucraid |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.